Ipca Laboratories Ltd

IPCALAB04 Dec 2024
Pharmaceuticals
-14.25 (-0.95%)
Lowest Today
Highest Today
Today’s Open
Prev. Close
52 Week High
52 Week Low
To Invest in Ipca Laboratories Ltd
Ipca Laboratories Ltd
Pharmaceuticals
IPCALAB04 Dec 2024
-14.25 (-0.95%)
1D
1M
6M
1Y
5Y
All

Ipca Laboratories Ltd - Share Price & Details

Traded Volume
Market Cap(Cr)
Avg Traded Price
1 Year return
31.53%
Upper Circuit
Lower Circuit
P/E TTM
54.64
P/B Ratio
5.66
Traded Value(Cr)
0.87
EPS TTM
27.5
Book value
Dividend
0.27%

Invest in Ipca Laboratories Ltd at ZERO Brokerage for 30 days

Price Performance

-4.05 %
1 Wk
-5.21 %
1 M
7.39 %
3 M
31.53 %
1 Y
34.25 %
YTD

Traded Volume Movement

Technical Details

Support 3
1444
Support 2
1461
Support 1
1475
Pivot Point :
1492
Resistance 1
1506
Resistance 2
1523
Resistance 3
1537

Peer Comparison

Scrip NamePriceDaily ChangeM.Cap (Cr)1 Year Returns %P/E (TTM)PB Ratio
Ipca Laboratories Ltd
₹1,488.50(-14.25/-0.95%)
1,488.50-14.2538,125.4031.5354.645.66
Lupin Ltd
₹2,093.70(+12.05/0.58%)
2,093.70+12.0594,964.3765.1431.684.32
Alembic Pharmaceuticals Ltd
₹1,095.80(-3.50/-0.32%)
1,095.80-3.5021,608.1846.3528.224.30
J B Chemicals & Pharmaceuticals Ltd
₹1,819.00(+22.70/1.26%)
1,819.00+22.7027,916.2522.0846.558.85
390.85-3.102,312.70-13.4823.091.40
Sanofi India Ltd
₹6,324.35(-31.25/-0.49%)
6,324.35-31.2514,636.95-21.5834.7621.40

About Ipca Laboratories Ltd

Ipca Laboratories Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 38119.06 crores. It has reported a sales of Rs. 1810.94 crores and a net profit of Rs. 244.12 crores for the quarter ended December 2018. The company management includes Premchand Godha, Premchand Godha,A K Jain,Pranay Godha,Prashant Godha,Kamal Kishore Seth,Narendra Mairpady,Harish P Kamath,Swati Patankar,Vivek Shiralkar (Ipca Laboratories Ltd) among others.
Chairman
Premchand Godha
Registered office
48 Kandivli Industrial Estate,Kandivli (West),Mumbai,Maharashtra,400067
FAX :91-22-28686613
Background
Incorporation Year1949
Face Value₹1
Market Lot1

Latest News

📢 Benchmark indices open on a flat note today; Nifty near 24,500

📈 Amid mixed global cues, benchmark indices started on a flat note today.
📊 At 9:16 AM, the Sensex gained 73.71 points or 0.09% at 80,919.46 and the Nifty was up 14.75 points or 0.06% at 24,471.90. 📢HDFC Bank(⬆️0.27%), Adani Ports (⬆️0.57%) and Axis Bank (⬆️0.23%) appeared as the top performers on the Nifty50 at open. Wipro, RVNL, and IEX stocks are in focus today.
04 Dec 2024 | 09:20 AM

📢 Benchmark indices open on a flat note today; Nifty near 24,500

📈 Amid mixed global cues, benchmark indices started on a flat note today.
📊 At 9:16 AM, the Sensex gained 73.71 points or 0.09% at 80,919.46 and the Nifty was up 14.75 points or 0.06% at 24,471.90. 📢HDFC Bank(⬆️0.27%), Adani Ports (⬆️0.57%) and Axis Bank (⬆️0.23%) appeared as the top performers on the Nifty50 at open. Wipro, RVNL, and IEX stocks are in focus today.
04 Dec 2024 | 09:20 AM

Vertex Securities Consolidated September 2024 Net Sales at Rs 2.71 cr

Reported Consolidated quarterly numbers for Vertex Securities are: Net Sales at Rs 2.71 crore in September 2024 up 32.32% from Rs. 2.05 crore in September 2023. Quarterly Net Profit at Rs. 0.19 crore in September 2024 up 2558.33% from Rs. 0.01 crore in September 2023. EBITDA stands at Rs. 0.36 crore in September 2024 up 111.76% from Rs. 0.17 crore in September 2023.
04 Dec 2024 | 03:16 PM

VASHU BHAGNANI Consolidated September 2024 Net Sales at Rs 1.03 crore

Reported Consolidated quarterly numbers for VASHU BHAGNANI INDUSTRIES are: Net Sales at Rs 1.03 crore in September 2024 down 92.97% from Rs. 14.64 crore in September 2023. Quarterly Net Profit at Rs. 0.20 crore in September 2024 down 38.21% from Rs. 0.32 crore in September 2023. EBITDA stands at Rs. 0.50 crore in September 2024 down 29.58% from Rs. 0.71 crore in September 2023.
04 Dec 2024 | 03:14 PM

Medico Intercontinental Consolidated Sept 2024 Net Sales at Rs 37.24 cr

Reported Consolidated quarterly numbers for Medico Intercontinental Limited are: Net Sales at Rs 37.24 crore in September 2024 up 117.47% from Rs. 17.12 crore in September 2023. Quarterly Net Profit at Rs. 1.63 crore in September 2024 up 87.49% from Rs. 0.87 crore in September 2023. EBITDA stands at Rs. 2.83 crore in September 2024 up 102.14% from Rs. 1.40 crore in September 2023.
04 Dec 2024 | 03:12 PM

How to buy Ipca Laboratories Ltd shares on nse?

To buy Ipca Laboratories Ltd shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the Ipca Laboratories Ltd share price today?

The Ipca Laboratories Ltd shares price on nse is Rs.1488.5 today.

What is the market cap of Ipca Laboratories Ltd shares on NSE ?

The company has a market capitalization of Rs.38125.40Cr

What is the PE & PB ratio of Ipca Laboratories Ltd shares ?

PE is 54.64 and PB is 5.66

What is the 52 Week High and Low of Ipca Laboratories Ltd shares?

Ipca Laboratories Ltd stock price high: Rs.1708.65 Ipca Laboratories Ltd stock price low: Rs.1041

Is Ipca Labs a government-run institution?

No, IPCA Laboratories is not a government-run organization. It is a privately-owned pharmaceutical company based in India. IPCA Laboratories was founded in 1949 and has since grown to become one of the leading pharmaceutical companies in India.

Who is Ipca Labs’ owner?

IPCA Laboratories is a publicly-traded company and its ownership is spread among its shareholders. The Promoter of IPCA Labs is Mr. Premchand Godha and his family.

How well is Ipca Labs doing?

IPCA Laboratories operates in the pharmaceutical industry and has a diverse product portfolio that includes medicines for various therapeutic segments, including antimalarials, anti-bacterial, pain management, and cardiovascular drugs.

Ipca Labs’ consolidated revenue has gone from Rs. 3773.18 crores in March 2019 to  Rs. 5,829.79 crores on 31 March 2022. The net profit has gone from Rs. 443.03 crores to Rs. 910.95 crores in the same period.

Ipca Labs stock has given a positive return of 10.05% over the past three years and a negative return of -18.57% over the past one year.

 

What are the latest results of Ipca Labs?

The last fiscal result of Ipca Labs was declared in March 2022 and they reported a consolidated revenue of INR 5,829.79 crore and net profit of Rs. 910.95 crores.

What are the potential catalysts that positively impact the stock price of Ipca lab?

Some potential catalysts that may positively affect IPCA Laboratories' stock price could include:

  • Strong financial results
  • Expansion in new markets
  • Launch of new products
  • Regulatory approvals
  • Industry trends
Click here to see your activities